The prevention and treatment of autoimmune disease in humans (as well as other animals) is described through the use of ligands directed to cytokines. Antibodies and receptors to the proinflammatory cytokines IL-2, TNF, IL-12 and IFN-gamma are employed (along with other ligands to such cytokines). Such ligands administered luminally are effective (as demonstrated in two experimental models of autoimmune disease) at delaying the onset of autoimune disease.

La prevención y el tratamiento de la enfermedad autoinmune en seres humanos (así como otros animales) se describe con el uso de los ligands dirigidos a los cytokines. Los anticuerpos y los receptores a los cytokines proinflammatory IL-2, TNF, IL-12 e IFN-gamma se emplean (junto con otros ligands a tales cytokines). Tales ligands administrados luminally son eficaces (según lo demostrado en dos modelos experimentales de enfermedad autoinmune) en delaying el inicio de la enfermedad del autoimune.

 
Web www.patentalert.com

< Clostridial toxin disease therapy

< Vaccine and antitoxin for treatment and prevention of C. difficile disease

> Clostridial toxin disease therapy

> Treatment with polyvalent antivenom containing immunoglobulin which is greater than 50% venom-reactive

~ 00029